Solid dosage form with polymeric binder
First Claim
1. A solid dosage form comprising at least one polymeric binder, and at least one active ingredient wherein the polymeric binder consists essentially of copolymerization units ofa) 30-65% by weight of at least one N-vinyllactam of the formula I in which n is 1,2, or 3,b) 20-55% by weight of methyl methacrylate, c) 15-50% by weight of at least one other monomer selected from vinyl esters of aliphatic C1-C22-carboxylic acids, esters of α
- , β
-ethylenically unsaturated C3-C8-mono- and dicarboxylic acids wight C1-C8-alkanols, C1-C4-diols or di-(C1-C4-alkyamino-C1-C4-alkanols, amides, nitrites, and cyclic anhydrides of the carboxylic acids, and d) 0-5% by weight of at least on α
, β
-ethylenically unsaturated acid selected from C3-C8-mono- and -dicarboxylic acids, noncyclic anhydrides of these carboxylic acids, monoesters of the C3-C8-dicarboxylic acids, α
, β
-ethylenically unsaturated sulfonic acids and the salts or quaternized products thereof.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to a solid dosage form comprising at least one polymeric binder and at least one active ingredient and, where appropriate, conventional additives, wherein the polymeric binder consists of copolymerized units a) 15-83% by weight of at least one N-vinyllactam, b) 15-83% by weight of methyl methacrylate, c) 2-70% by weight of at least one other monomer and d) 0-9.9% by weight of at least one α,β-ethylenically unsaturated acid.
-
Citations
4 Claims
-
1. A solid dosage form comprising at least one polymeric binder, and at least one active ingredient wherein the polymeric binder consists essentially of copolymerization units of
a) 30-65% by weight of at least one N-vinyllactam of the formula I in which n is 1,2, or 3, b) 20-55% by weight of methyl methacrylate, c) 15-50% by weight of at least one other monomer selected from vinyl esters of aliphatic C1-C22-carboxylic acids, esters of α - , β
-ethylenically unsaturated C3-C8-mono- and dicarboxylic acids wight C1-C8-alkanols, C1-C4-diols or di-(C1-C4-alkyamino-C1-C4-alkanols, amides, nitrites, and cyclic anhydrides of the carboxylic acids, andd) 0-5% by weight of at least on α
, β
-ethylenically unsaturated acid selected from C3-C8-mono- and -dicarboxylic acids, noncyclic anhydrides of these carboxylic acids, monoesters of the C3-C8-dicarboxylic acids, α
, β
-ethylenically unsaturated sulfonic acids and the salts or quaternized products thereof.- View Dependent Claims (2, 3, 4)
- , β
Specification
-
- Resources
-
Current AssigneeBASF AG (BASF SE)
-
Original AssigneeBASF AG (BASF SE)
-
InventorsBerndl, Gunther, Meffert, Helmut, Kothrade, Stephan
-
Primary Examiner(s)Travers, Russell
-
Assistant Examiner(s)WANG, SHENGJUN
-
Application NumberUS09/395,775Time in Patent Office721 DaysField of Search514/772.1, 514/772.2, 424/465, 424/476, 424/482US Class Current514/772.1CPC Class CodesA61K 9/2027 obtained by reactions only ...A61K 9/2095 Tabletting processes; Dosag...
